CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 191 enrolled / 191 target
Drug / intervention
Fluvoxaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05874037
NCT05874037Phase 2CompletedHigh Momentum (5.1/mo)Completion was 15mo ago
CompareCT.gov

Fluvoxamine as a Treatment for Long COVID-19: A Randomized Placebo Controlled Trial

Washington University School of Medicine·interventional·Posted May 24, 2023·Updated Jun 25, 2026

In Brief

A Phase 2 clinical trial evaluating Fluvoxamine for Long COVID. Completed, enrolled 191 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is testing whether fluoxamine helps to improve symptoms and the negative impacts of long COVID in residents of Missouri and Illinois.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLong COVID
CountriesUnited States
CollaboratorsBalvi COVID Fund, BJH Townley Fund

Timeline

Phase 2CompletedFinished
202420252026
First PostedMay 24, 2023
Enrollment StartMay 15, 2023
Primary CompletionMar 15, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.1 years ago

Arms & Interventions

Fluvoxamineexperimental

Drug: Fluvoxamine
Placeboplacebo_comparator

Drug: Fluvoxamine

Interventions

Fluvoxaminedrug

Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.